Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
Session 5: Recent Cohort Studies

June 27, 1999

In order to assess the pattern of subcutaneous and visceral fat distribution and metabolic abnormalities among male patients treated with antiretrovirals, T. Saint-Marc and colleagues performed a cross sectional study of 154 men treated who received regimens with at least 2 antiretrovirals between August 1998 and February 1999. Seventy-two of the patients were determined to have normal fat distribution and metabolism; 22% of the patients showed lipoatrophy; 5.9% of subjects had pseudo-obesity; and 25.3% showed a mixture of the syndromes. Among patients with lipoatrophy and pseudo-obesity, those receiving d4T had different subcutaneous adipose tissue and triglyceride levels compared to those receiving AZT. Lipoatrophy was associated with d4T use as part of nucleoside reverse transcriptase inhibitor (NRTI) or protease inhibitor (PI) therapy, when compared with patients on AZT.

The authors further examined the effects of d4T discontinuation on metabolic abnormalities in patients on either NRTI therapy or PI therapy. Triglyceride and pyruvate levels decreased among patients who discontinued d4T in both groups, but no difference was observed in cholesterol or glucose levels compared to controls who remained on d4T. Patients who discontinued d4T showed increased body fat in the abdomen and mid-thigh subcutaneous fat region. Some patients, though, continued to worsen despite the discontinuation of d4T.

The authors believe that d4T use is associated with fat depletion in the abdominal and mid-thigh subcutaneous adipose tissue. They failed to report antiretroviral history or patient characteristics, though, which limits the ability to interpret the data. Additionally, the subjects were not randomized, which could introduce bias into the study.

Abstract: Reversability of Peripheral Fat Wasting (Lipoatrophy) on Stopping Stavudine (d4T) Therapy (Abstract 24)
Authored by: T. Saint-Marc and J.L. Touraine

Abstract: Changes in Body Fat Distribution in 154 HIV-Infected Male Patients Treated with Combined Antiretroviral Therapy (Abstract 25)
Authored by: T. Saint-Marc, M. Partani, I. Poizot-Martin, F. Bruno, and O. Rouviere



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement